Cargando…

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

BACKGROUND: The single‐arm DAWN trial (NCT01779791) of ibrutinib monotherapy in patients with relapsed/refractory follicular lymphoma (FL) showed an overall response rate (ORR) of 20.9% and a median response duration of 19.4 months. This biomarker analysis of the DAWN dataset sought to determine gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balasubramanian, Sriram, Hodkinson, Brendan, Schuster, Stephen J., Fowler, Nathan H., Trotman, Judith, Hess, Georg, Cheson, Bruce D., Schaffer, Michael, Sun, Steven, Deshpande, Sanjay, Vermeulen, Jessica, Salles, Gilles, Gopal, Ajay K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704158/ https://www.ncbi.nlm.nih.gov/pubmed/34791836 http://dx.doi.org/10.1002/cam4.4422

Ejemplares similares

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
por: Hodkinson, Brendan P., et al.
Publicado: (2020)

Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
por: Pongas, Georgios, et al.
Publicado: (2021)

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic
por: Chauhan, Ayushi F, et al.
Publicado: (2021)

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
por: Johnson, Peter W. M., et al.
Publicado: (2023)

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
por: Bruscaggin, Alessio, et al.
Publicado: (2021)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

Impact of obinutuzumab alone and in combination for follicular lymphoma
por: Sarraf Yazdy, Maryam, et al.
Publicado: (2017)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature
por: Chauhan, Ayushi F, et al.
Publicado: (2020)

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
por: Salles, Gilles, et al.
Publicado: (2022)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
por: Zhu, Jun, et al.
Publicado: (2022)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022)

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes
por: Proudman, David G., et al.
Publicado: (2022)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Ibrutinib-Induced Skin Rash
por: Kirar, Sudhir, et al.
Publicado: (2021)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
por: Dreyling, Martin, et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma
por: Deak-Mihaly, Dalma, et al.
Publicado: (2021)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Time for an individualized approach to first-line management of follicular lymphoma
por: Cartron, Guillaume, et al.
Publicado: (2022)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

The temple of dawn
por: Mishima, Yukio, 1925-1970
Publicado: (1970)

The dawn of magic
por: Pauwels, Louis
Publicado: (1964)

The Dawn of Litholapaxy
Publicado: (1900)

The Dawn of Character
Publicado: (1911)

Controversies in the Treatment of Follicular Lymphoma
por: Hübel, Kai, et al.
Publicado: (2020)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
por: Nepal, Gaurav, et al.
Publicado: (2022)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib
por: Teixeira, Larissa Lane Cardoso, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
por: Novak, Urban, et al.
Publicado: (2023)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
por: Wang, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0lrol0v019u9mcaamfsbfpip9s